C4 Therapeutics announced new positive biomarker data for its drug cemsidomide from two clinical trials in patients with relapsed/refractory multiple myeloma (RRMM). The data, presented at the 23rd International Myeloma Society (IMS) Annual Meeting, support cemsidomide's immunomodulatory activity. The company also announced the advancement of its Phase 1b combination trial after a key safety milestone was met.
Key Details
- Phase 1 Trial Data (cemsidomide + dexamethasone): In 62 RRMM patients, cemsidomide demonstrated T-cell activation and functional reprogramming of natural killer (NK) cells, particularly at higher dose levels (75 µg and 100 µg).
- Phase 1b Trial Advancement (cemsidomide + elranatamab): The safety data review committee declared the 75 µg cemsidomide dose level safe in combination with elranatamab. The trial will now advance into a 100 µg dose escalation cohort and a 75 µg dose expansion cohort.
- Future Data Timeline: Data from all cohorts in the ongoing Phase 1b trial are expected in mid-2027.